Abhiflax Pharma-Chem Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 08-07-2024
- Paid Up Capital ₹ 0.48 M
as on 08-07-2024
- Company Age 30 YEARS, 3 MONTHS
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 12.40 M
as on 08-07-2024
- Revenue 13.11%
FY 2022
- Profit 26.17%
FY 2022
- Ebitda -72.61%
FY 2022
- Net Worth 67.26%
FY 2022
- Total Assets 35.04%
FY 2022
About Abhiflax Pharma-Chem
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.48 M.
The company currently has active open charges totaling ₹1.24 Cr.
Abhishek Bajoria and Navin Bajoria serve as directors at the Company.
- CIN/LLPIN
U24239MH1994PTC079333
- Company No.
079333
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jun 1994
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Abhiflax Pharma-Chem Private Limited offer?
Abhiflax Pharma-Chem Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Cardiovascular Drugs & Medication, Antidiabetic Medicine, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, TB, Tumor & Cancer Drugs, Anti Cancer Medicines.
Who are the key members and board of directors at Abhiflax Pharma-Chem?
Board Members(2)
Financial Performance and Corporate Structure Insights of Abhiflax Pharma-Chem.
Abhiflax Pharma-Chem Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 13.11% increase. The company also saw a substantial improvement in profitability, with a 26.17% increase in profit. The company's net worth Soared by an impressive increase of 67.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Abhiflax Pharma-Chem?
In 2021, Abhiflax Pharma-Chem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Abhiflax Life Science Limited
Active
1 year 9 months Abhishek Bajoria and Navin Bajoria are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 13 Dec 2013 | ₹1.24 Cr | Open |
How Many Employees Work at Abhiflax Pharma-Chem?
Unlock and access historical data on people associated with Abhiflax Pharma-Chem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Abhiflax Pharma-Chem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Abhiflax Pharma-Chem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
